Annals of Surgical Oncology

, Volume 16, Issue 1, pp 51–60 | Cite as

A Proposed Staging System for Gastric Carcinoid Tumors Based on an Analysis of 1,543 Patients

  • Christine S. Landry
  • Guy Brock
  • Charles R. Scoggins
  • Kelly M. McMasters
  • Robert C. G. MartinIIEmail author
Gastrointestinal Oncology


The lack of a clinically relevant staging system for gastric carcinoid tumors creates a persistent challenge for clinicians trying to provide patients with meaningful prognostic information. The purpose of this study was to identify the clinicopathologic factors that affect survival for patients diagnosed with gastric carcinoid, and use this information to create a staging system. A search of 15,983 patients with carcinoid tumors from the Surveillance Epidemiology and End Results (SEER) database identified 1,543 patients with gastric carcinoid tumors from 1973 to 2004. Patients were analyzed according to various clinicopathologic factors, and a tumor (T1, T2, T3), lymph node (N0, N1), and metastasis (M0, M1) staging system was created according to these parameters. Gastric carcinoid was the only primary malignancy in 74% of patients; 24% presented with one additional primary malignancy, and 2.7% had two or more additional malignancies. On multivariate analysis, age and depth of invasion were significant for patients with one tumor. Four stages were created according to statistically significant prognostic factors: 60% of patients were classified into stage I, 7.6% into stage II, 6.5% into stage III, and 26% into stage IV. Five-year survival rates were 82, 63, 21, and 5.5% for stages I–IV, respectively. We conclude that this tumor–node–metastasis (TNM) staging system accurately discriminates prognosis for all types of gastric carcinoid tumors, with size, depth of invasion, lymph node involvement, and distant metastasis having the greatest impact on survival. Incorporation of this staging system into clinical practice will allow better study of outcomes and development of stage-specific treatment recommendations.


Distant Metastasis Staging System Carcinoid Tumor Muscularis Propria Primary Malignancy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Hou W, Schubert ML. Treatment of gastric carcinoids. Curr Treat Options Gastroenterol. 2007;10:123–33.CrossRefPubMedGoogle Scholar
  2. 2.
    Borch K, Ahren B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. World J Surg. 2005;242:64–73.Google Scholar
  3. 3.
    Burkitt MD, Pritchard DM. Review article: Pathogenesis and management of gastric carcinoid tumours. World J Surg. 2006;24:1305–20.Google Scholar
  4. 4.
    Seya T, Shinji E, Tanaka N, et al. A case of multiple gastric carcinoids that could not be preoperatively diagnosed. J Nippon Med Sch. 2007;74:430–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Gastrointestinal carcinoids: characterization by site of origin and hormone production. World J Surg. 2004;99(232):23–32.Google Scholar
  6. 6.
    Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006.CrossRefPubMedGoogle Scholar
  7. 7.
    Berna MJ, Annibale B, Marignani M, et al. A prospective study of gastric carcinoids and enterochromaffin-like cell changes in Multiple Endocrine Neoplasia Type I and Zollinger-Ellison syndrome: identification of risk factors. J Clin Endocrinol Metab. 2008;93:1582–91.Google Scholar
  8. 8.
    Feldman M, Friedman L, Brandt L. Sleisenger and Fordtran’s gastrointestinal and liver disease. Philadelphia, PA: Saunders Elsevier; 2006.Google Scholar
  9. 9.
    Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. World J Surg. 2003;97:934–59.Google Scholar
  10. 10.
    Liu Y, Liang H, Liu N, et al. Relationship of biological behavior and the prognosis in gastric carcinoid. Zhonghua Wei Chang Wai Ke Za Zhi 2007;10:472–5.PubMedGoogle Scholar
  11. 11.
    Hosokawa O, Kaizaki Y, Hattori M, et al. Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer. 2005;8:42–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Thomas RM, Baybick JH, Elsayed AM, et al. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer. 1994;73:2053–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. World J Surg. 2005;103(232):1587–95.Google Scholar
  14. 14.
    Gough DB, Thompson GB, Crotty TB, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg. 2008;18:473–80.CrossRefGoogle Scholar
  15. 15.
    Kadikoylu G, Yavasoglu I, Yukselen V, et al. Treatment of solitary gastric carcinoid tumor by endoscopic polypectomy in a patient with pernicious anemia. World J Gastroenterol. 2006;12:4267–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2008

Authors and Affiliations

  • Christine S. Landry
    • 1
  • Guy Brock
    • 2
  • Charles R. Scoggins
    • 1
  • Kelly M. McMasters
    • 1
  • Robert C. G. MartinII
    • 1
    Email author
  1. 1.Division of Surgical Oncology, Department of Surgery and James Graham Brown Cancer CenterUniversity of Louisville School of MedicineLouisvilleUSA
  2. 2.Department of Bioinformatics and BiostatisticsSchool of Public Health and Information SciencesLouisvilleUSA

Personalised recommendations